Healthcare
Microbot Medical Inc.(MBOT)
Live Price
Offline$1.78
-2.20% today
1Y Change
-26.94%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $100.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +60.3%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Microbot Medical Inc. (MBOT) is a Healthcare stock with a market cap of $100.00M and listed on NASDAQ. The stock last traded around $1.78 and down 26.9% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +60.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +60.3%, free cash flow -48.1% with operating margin 0.0% and ROIC -18.8%. Stock Foundry combines MBOT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +60.3%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -14.7% | -19.8% | -16.1% |
2026 Mar 26, 2026 | +33.3% | -8.8% | -8.4% | -16.0% |
2025 Nov 12, 2025 | -16.7% | -6.1% | -9.4% | +12.3% |
Benchmark Edge
MBOT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MBOT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MBOT Max Drawdown
-64.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MBOT and SPY.
Company Overview
Microbot Medical Inc.
NASDAQ Capital Market
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
- Leadership
- Harel Gadot
- IPO Date
- Mar 25, 1992
- Employees
- 20
- Street Address
- 25 Recreation Park Drive
- Mailing
- Hingham, MA, 02043
- Region
- Hingham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 875 3605
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.8
Growth
- Revenue
- 0.0%
- EPS
- +60.3%
- Free Cash Flow
- -48.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -24.4%
- ROIC
- -18.8%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 23.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.